William Blair initiates Enliven Therapeutics stock with outperform rating

William Blair initiated coverage on Enliven Therapeutics (NASDAQ:ELVN) with an outperform rating, noting the chronic myeloid leukemia market is expanding and requires more effective, tolerable, and convenient treatment options. The stock has surged 287% year-to-date, trading near its 52-week high, though it appears overvalued at current levels.

Analysts estimate the total addressable market for CML to be roughly $8.8 billion, including $5.6 billion from the United States. Enliven Therapeutics has completed a significant public offering, raising approximately $460 million in gross proceeds, while other analysts such as Barclays, Guggenheim, H.C. Wainwright, and Jones Trading have also provided coverage with varying ratings and price targets.

Brief written by urgent.news from Investing.com's own syndicated text. Machine-written — may contain errors; check the original before relying on it.